Global Large Volume Wearable Injectors demand is anticipated to be valued at USD 2,800.0 Million in 2022, forecast to grow at a CAGR of 8.9% to be valued at USD 7,142.3 Million from 2022 to 2032. Growth is attributed to the shift of healthcare delivery toward home care.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2022) | USD 2,800.0 Million |
| Anticipated Forecast Value (2032) | USD 7,142.3 Million |
| Projected Growth Rate (2022 to 2032) | 8.9% CAGR |
Large Volume Injectors are used to administer a relatively large volume of medication in a short duration. They are commonly used for the rapid administration of medication in emergency cases for achieving peak drug concentration in blood plasma. Large-volume injectors are used to administer biological drug formulations, particularly those containing monoclonal antibodies because the biological formulation is viscous at high concentrations.
Therefore, a large volume is ideal for depot administrations and infrequent dosing. Large-volume injectors also decrease the dosing frequency which eliminates the dosing errors in medical facilities. Large-volume injectors are also used for regular dosing of incremental biological therapy in chronic disease indications. They also provide product differentiation through increased efficacy, safety, convenience, and tolerability.
Factors such as the advantages of wearable injectors in the administration of various drugs are expected to boost the growth of the Large Volume Wearable Injectors market in the near future.
On the other hand, the preference for alternative drug delivery modes is one of the major factors that is expected to hamper the growth of the Large Volume Wearable Injectors Market over the analysis period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Large Volume Injectors reduce the injection workflow, are safer to use, and facilitate self-administration. Infusion site hypersensitivity reactions are the major issues for biological formulations. Reactions include pain, and swelling and may lead to fever, nausea, and headache.
To mitigate the risk of hypersensitivity reactions, such formulations are administered by slow infusion for several hours. These factors are expected to accelerate the growth of the Large Volume Wearable Injectors Market during the forecast period.
Factors such as the shift of healthcare delivery toward homecare due to COVID-19, advantages of wearable injectors in the administration of various drugs, the rising prevalence of chronic diseases (such as cancer, diabetes, and CVD), favorable reimbursement scenario in major markets, and technological advancements in injector devices are also expected to flourish the growth of the Large Volume Wearable Injectors over the analysis period.
The ability of large-volume injectors enables ambulatory drug delivery with increased safety driving the growth of the large-volume injectors market. In certain care pathways, patients need to be present for infusion on a regular basis to receive drug therapy for the extended treatment period.
These are because in most cases health care supervision is required for administrations of infusions. In such cases, large volume injectors increase the ability for patients to self-administration reduce the burden and increase patient compliance. Rising demand due to improved safety and efficacy drives the burgeoning growth of the large-volume injectors market.
A growing focus on the use of biologics and mAbs to treat diseases such as rheumatoid arthritis, cardiovascular disease, and cancer will provide significant growth opportunities for wearable injectors, as these drugs need to be administered via the parenteral route (intravenous, subcutaneous, or intramuscular delivery). All these factors are expected to offer lucrative opportunities for market growth in the near future.
Large-volume injectors administer 3ml or greater and may not frequently administer. They are little evidence-based data with appropriate use, potential efficacy, and side effects which is one of the major factors that is expected to hinder the growth of the large volume injectors during the forecast period.
The preference for alternative drug delivery modes, high costs, and a poor reimbursement structure in developing countries are some other factors that are anticipated to impede the growth of the large volume wearable injectors market in the forthcoming years.
Principal Consultant
In terms of regional platforms, North America holds the largest market share in the Large Volume Wearable Injectors market. The region is expected to surge to over 35.6% share from 2022 to 2032.
North America is expected to fuel the Large Volume Wearable Injectors market, attributed to the increased acceptance by the end-user population, and high penetration.
In terms of regional platforms, North America holds the largest market share in the Large Volume Wearable Injectors market. The region is expected to surge to over 35.6% share from 2022 to 2032.
North America is expected to fuel the Large Volume Wearable Injectors market, attributed to the increased acceptance by the end-user population, and high penetration.
According to Future Market Insights, Europe is expected to hold lucrative growth opportunities for Large Volume Wearable Injectors and is expected to reach a significant share of 33.1% in 2022. Europe is expected to witness significant market growth, owing to rising awareness of the Large Volume Injectors Market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
According to Future Market Insights, Asia-Pacific is expected to grow with lucrative growth opportunities for Large Volume Wearable Injectors and is expected to reach a market share of 25.6% in 2022.
Asia-Pacific region accounts for a significant share of the Large Volume Wearable Injectors Market, attributed to continuous advancements in medical wearable technologies, which are boosting the prospects of the regional market, and is propelled increasingly by the growing burden of chronic diseases.
According to Future Market Insights, the Middle East & Africa are expected to provide significant growth opportunities for Large Volume Wearable Injectors Market and are expected to reach a share of 12.3% in 2022.
The developing Large Volume Wearable Injectors market in the Middle East & Africa is expected to aid in the flourishing market during the forecast period, owing to rapid industrialization in the developing countries of the region.
There are many prominent market players in the Large Volume Wearable Injectors Market such as Ypsomed Holding AG, Gerresheimer AG (Sensile Medical), West Pharmaceutical Services Inc., Unilife Corporation, SteadyMed Therapeutics, Inc., Enable Injections, Medgizmo, West Pharmaceutical Services, Inc., Terumo Corporation, and Sorrel Medical, among others, that are working hand-in-hand to provide the best-in-class Large Volume Wearable Injectors for enhancing the global Large Volume Wearable Injectors arena.
However, there are many global start-ups in the Large Volume Wearable Injectors Market, that are stepping forward in matching the requirements of the Large Volume Wearable Injectors domain.
Some of the key participants present in the global Large Volume Wearable Injectors market include Elcam Medical, Debiotech S.A, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., F. Hoffmann-La Roche Ltd., Amgen, Inc., Insulet Corporation, CeQur SA, Medtronic Plc, Tandem Diabetes Care, Inc., and PerkinElmer Inc., among others.
Attributed to the presence of such high number of participants, the market is highly competitive. While global players such as Elcam Medical, Debiotech S.A, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., F. and Hoffmann-La Roche Ltd. account for a considerable market size, several regional level players are also operating across key growth regions, particularly in North America.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 8.9% from 2022 to 2032 |
| Market Value in 2022 | USD 2,800.0 Million |
| Market Value in 2032 | USD 7,142.3 Million |
| Base Year for Estimation | 2021 |
| Historical Data | 2016 to 2021 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Million, Volume in Kilotons, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | End-User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | United States of America, Canada, Brazil, Argentina, Germany, United Kingdom, France, Spain, Italy, Nordics, Belgium, Netherlands, Luxembourg, Poland, Russia, Australia & New Zealand, China, India, ASIAN, GCC Countries, South Africa |
| Key Companies Profiled | Elcam Medical; Debiotech S.A; Becton; Dickinson and Company; Johnson & Johnson Services, Inc.; F. Hoffmann-La Roche Ltd.; Amgen, Inc.; Insulet Corporation; CeQur SA; Medtronic Plc; Tandem Diabetes Care, Inc.; and PerkinElmer Inc.; among others. |
| Customization | Available Upon Request |
FMI projects the global Large Volume Wearable Injectors market to expand at an 8.9% value CAGR by 2032
North America is expected to be the most opportunistic Large Volume Wearable Injectors market, expanding at a 35.6% market share
Elcam Medical, Debiotech S.A, Becton, Dickinson, and Company, Johnson & Johnson Services, Inc., and F. Hoffmann-La Roche Ltd. are some prominent Large Volume Wearable Injectors players
1. Executive Summary | Large Volume Wearable Injectors Market 2. Market Overview 3. Market Background 4. Global Market Analysis 2016 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By End User 5.1. Hospitals 5.2. Clinics 5.3. Ambulatory Surgical Centers 5.4. Research Institutes 6. Global Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Region 6.1. North America 6.2. Latin America 6.3. Europe 6.4. Asia Pacific 6.5. Middle East and Africa 7. North America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country 8. Latin America Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country 9. Europe Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country 10. Asia Pacific Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country 11. Middle East and Africa Market Analysis 2016 to 2021 and Forecast 2022 to 2032, By Country 12. Key Countries Market Analysis 13. Market Structure Analysis 14. Competition Analysis 14.1. Becton, Dickinson, and Company 14.2. PerkinElmer, Inc. 14.3. Medgizmo 14.4. West Pharmaceutical Services 14.5. Unilife Pharmachem Private Limited 14.6. SteadyMed Ltd. 14.7. Roche Holding AG 14.8. CeQur Corporation 14.9. Scpharmaceuticals Inc. 14.10. Sensile Medical AG 15. Assumptions & Acronyms Used 16. Research Methodology
Explore Healthcare Insights
View Reports
Large Volume Wearable Injectors Market
